Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

g new era of patient friendly oncology therapy," said Mr. Duggan, CEO and Chairman of the Board.

ASCO Conference Call and Webcast Details
Date: Monday, June 6, 2011
Time: 4:30 pm ET
Participant Dial In (Toll Free): 877-407-8133
Participant Dial In (International): 201-689-8040

Slides used in the ASCO presentation from today and during the conference call are posted on the Investor Relations Section of our website, under Events & Webcasts: http://ir.pharmacyclics.com/events.cfm

To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

Large unmet needs in Non-Hodgkin's Lymphoma (NHL) Market
There are over 25 distinct subtypes of B-cell malignancies; the common NHLs include the following: follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma. The NHL therapy market will experience robust annual growth (7.6% per year) and more than double in size over the years 2009-2019 from approximately $4.1 billion in 2009 to approximately $8.4 billion in 2019, as forecasted by Decision Resources, Inc. in the Non-Hodgkin's Lymphoma Onkos Study, April 2011.

There are significant and distinct areas of unmet medical need across the NHL subtypes.  Within the indolent lymphomas, we believe a need exists for active therapies that avoid the toxicities typically seen with conventional chemotherapies. Such active therapies are needed as part of effective combinations early in the course of treatment, and also as effective single-agent treatments later in the c
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NASHVILLE, Tenn. , Sept. 19, 2014  Over ... for the Future to Benefit the Radiation Oncology Institute ... was held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... sponsorships, we have raised over $70,000 for the ROI ...
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... offering of passive safety devices to protect both clinicians ... Inc. (B. Braun) recently announced that the U.S. Food ... company,s Introcan Safety ® 3 Closed IV Catheter, ... IV Catheter. B. Braun made the announcement during ...
... goBalto , developer of new ... has raised an undisclosed amount in Series A financing ... and the West Health Investment Fund.  The funds ... to enhance Tracker™ , its Software-as-a-Service (SaaS) clinical ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2goBalto Raises Series A Financing to Advance Cloud-based Health Technologies 2goBalto Raises Series A Financing to Advance Cloud-based Health Technologies 3
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web ... Bluehost are the best suppliers of 2014. Clients ... (including VPS and cloud hosting) at affordable rates ... , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies ... of the cost. As a top rated hosting ...
(Date:9/19/2014)... cancer do not receive any palliative care, reveals new ... ESMO 2014 Congress in Madrid, Spain, 26-30 September. The ... time as 15 new oncology centres in Europe, Canada, ... title of ,ESMO Designated Centre of Integrated Oncology and ... oncology consultant at the Institute of Oncology Bucharest, Romania, ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Immunoassays are ligand assays used for detection ... antibodies in a given sample. Driven by steady ... overall healthcare industry, the global immunoassay systems market ... incidence of debilitating conditions, such as diabetes, cardio-vascular ...
(Date:9/19/2014)... TN (PRWEB) September 19, 2014 ... has been named a finalist for the 2014 ... founder and president Tammy Hawes has been selected ... the Year. The Nashville Area Chamber of Commerce ... these awards to recognize the accomplishments of companies ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... for about 10% to 20 % of women menopausal period ... sweats, hot// flashes (sensation of heat which comes on all ... Therapy (HRT) is the conventional treatment of choice that is ... period. Hormone therapy offers great relief from hot flashes and ...
... Telemedicine, the amalgamation of medicine and modern communications technology, ... monitor patients at a distance means they// can leave ... doctor, which also saves money. ,Christian Weigand, ... Circuits in Erlangen, Germany, said telemedicine could help people ...
... olive oil, glycerine and egg yolk would prevent ... ,The journal of Catheterization and Cardiovascular Interventions ... by Michael Savage, M.D., director, Cardiac Catheterization Laboratory ... mixture is not swallowed, Dr. Savage explains. Rather, ...
... the aging brain produces progressively fewer new nerve ... scientists said the finding, made in rodents, refutes ... cells persist in the aging brain. ... various neurodegenerative disorders, including Alzheimer's disease, dementia and ...
... diabetes and heart disease, lifestyle changes are making a ... study suggests that by reducing the intake beverages saturated ... their risk of developing cardiac diseases in the future. ... hypertension and type-2 diabetes has largely dealt with adults," ...
... signal an oncoming cold, many people reach for what ... tea or capsule containing //echinacea. In the first study ... bacteria in the gastrointestinal tract, research at the University ... side effects with this common herbal remedy. ,Although ...
Cached Medicine News:Health News:Natural Remedies Ineffective to Ease Menopausal Symptoms:study 2Health News:Telemedicine Offers New Possibilities in Health Care 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2Health News:Stem Cell Activity Deciphered in the Aging Brain 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Echinacea: Cold-Season Cure or Risk? 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
... an independent laboratory to meet ... Standard 209E. Ergonomic seat guarantees ... back injuries. Clean vinyl meets ... chairs feature dissipative vinyl, conductive ...
Medicine Products: